Newsmeme!
Discover News you didn't know existed
Graft-versus-host Disease (Gvhd)
News
Related Video News
No related video news stories found.
Related Videos
No related videos found.
Kiadis Pharma to continue ATIR collaboration with Professor Velardi
Published November 30, 2008, 11:50 pm, PharmaBiz
Oncology focused biopharmaceutical company Kiadis Pharma announces that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR, a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease (GvHD) for end ...
Kiadis Pharma Announces Continued Collaboration With Professor Velardi On Its Lead Product ATIR(TM)
Published November 29, 2008, 4:11 am, Medical News Today
Oncology focused biopharmaceutical company Kiadis Pharma announces that Andrea Velardi, M.D.
Kiadis Pharma Announces Continued Collaboration With Professor Velardi on its Lead Product ATIR(TM)
Published November 28, 2008, 5:00 am, PR Newswire via Yahoo! Finance
Oncology focused biopharmaceutical company Kiadis Pharma announces today that Andrea Velardi, M.D., Professor of Clinical Immunology at the University of Perugia, Italy and Kiadis Pharma are continuing their collaboration on ATIR, a product in clinical development for enabling the use of a mismatched donor in a bone marrow transplantation by preventing acute Graft versus Host Disease for end ...
Chatham High School --Haunted Hallways†raises funds, awareness
Published November 28, 2008, 12:51 am, Chatham Courier
CHATHAM – The halls of Chatham High School were haunted – haunted with ghouls, goblins, and ghosts as the National Art Honors Society unleashed its first annual “Haunted Hallways” Thursday, Oct. 30
DOR BioPharma's orBec gets orphan drug status in Australia
Published November 27, 2008, 11:50 pm, PharmaBiz
DOR BioPharma, Inc, a late-stage biopharmaceutical company developing products to treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases, and vaccines against certain bioterrorism agents, announced that the Therapeutics Goods Administration (TGA) of Australia has designated orBec as an Orphan Drug for the treatment of patients with gastrointestinal ...
OrBec(R) Receives Orphan Drug Designation In Australia For The Treatment Of Gastrointestinal Graft-Versus-Host-Disease
Published November 25, 2008, 12:12 pm, Medical News Today
DOR BioPharma, Inc. (DOR or the Company) (OTCBB: DORB), a late-stage biopharmaceutical company, announced today that the Therapeutics Goods Administration (TGA) of Australia has designated orBec(R) as an Orphan Drug for the treatment of patients with gastrointestinal Graft-Versus-Host-Disease (GI GVHD) following allogeneic hematopoietic cell transplantation.
Related News Resources:
> HGH News
News Directory
Get started fast by using a pre-defined news directory category
|
Breaking News
and Top Stories |
Business
Earnings, Economy, Personal Finance, and Stock Markets |
Entertainment
Books, Celebrity, Fashion, Movies, Music, Television, and Theatre |
Health
Aging, Diseases, Medical Conditions, Medications, Sexual Health, and Weight Loss |
Politics
Congress, Supreme Court, and White House |
|
Science
Animals, Astronomy, Biotechnology, Space, and Weather |
Sports
Baseball, Basketball, Boxing, Football, Golf, Hockey, Motor Sports, Soccer, and Tennis |
Technology
Communications, Hardware, Internet, Personal Technology, and Software |
United States
and Crimes and Trials |
World
Africa, Antartica, Asia, Australia, Canada, Europe, Latin America, and Middle East |